mometasone furoate; 83919-23-7; Asmanex; Nasonex; Elocon; Monovo; Sch 32088; mometasone 17-furoate; Sinuva; Mometasone fuorate; Mometasone furoate anhydrous; Sch32088; Sch-32088; NSC-746171; CHEMBL1161; LYR210; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate; [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate; DTXSID4023333; Mometasone furoate hydrate; CHEBI:47564; LYR-210; 04201GDN4R; NSC-760077; (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione; Danitin; Ecural; Elomet; Asmanex Twisthaler; 9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate); 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; DTXCID003333; Elocone; Flumeta; Nosorex; Rimelon; Ovixan; Asmanex HFA; (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; MOF; UNII-04201GDN4R; mometasone-furoate; NCGC00016950-01; Prestwick_924; Asmanex (TN); Mometasone furoate [USAN:USP:JAN]; CAS-83919-23-7; Elocon (TN); LAS 41002; BRN 4340538; Prestwick0_000572; Prestwick1_000572; Prestwick2_000572; Prestwick3_000572; mometasone furancarboxylate; SCHEMBL4568; BSPBio_000384; Mometasone 17-(2-furoate); MLS002153879; SPBio_002603; Mometasone furoate (JAN/USP); BPBio1_000424; MOMETASONE FUROATE [MI]; MOMETASONE FUROATE [JAN]; MOMETASONE FUROATE [USAN]; HMS1569D06; HMS2096D06; HMS2235I14; HMS3713D06; MOMETASONE FUROATE [VANDF]; MOMETASONE FUROATE [MART.]; MOMETASONE FUROATE [USP-RS]; MOMETASONE FUROATE [WHO-DD]; ZINC3938677; Tox21_110705; AC-941; BDBM50148733; MFCD00866003; NSC746171; s1987; Mometasone furoate, >=98% (HPLC); AKOS015994732; Tox21_110705_1; CCG-220572; DB14512; KS-1275; MOMETASONE FUROATE [GREEN BOOK]; NSC 746171; NSC 760077; MOMETASONE FUROATE [ORANGE BOOK]; MOMETASONE FUROATE [EP MONOGRAPH]; NCGC00179578-01; NCGC00179578-03; NCGC00179578-04; DULERA COMPONENT MOMETASONE FUROATE; HY-13693; MOMETASONE FUROATE [USP MONOGRAPH]; SMR001233233; M2354; MOMETASONE FUROATE COMPONENT OF DULERA; C07817; D00690; A840685; EN300-19766989; Mometasone Furoate 100 microg/mL in Acetonitrile; SR-01000841209; LYR-220 ACTIVE COMPONENT MOMETASONE FUROATE; Q-101380; Q1044248; SR-01000841209-2; BRD-K60640630-001-03-7; BRD-K60640630-001-11-0; Mometasone furoate, European Pharmacopoeia (EP) Reference Standard; Mometasone furoate, United States Pharmacopeia (USP) Reference Standard; 11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate; Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material; (11.BETA.,16.ALPHA.)-9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE; (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; (1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-chloro-1-(2-chloroacetyl)-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate; [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate;Mometasone furoate; [(9R,10S,11S,13S,16R,17R)-9-Chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate; Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-; PREGNA-1,4-DIENE-3,20-DIONE, 9,21-DICHLORO-17-((2-FURANYLCARBONYL)OXY)-11-HYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.); Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-